GVK BIO: Goldman Sachs to provide exit to PE firm ChrysCapital, acquire significant minority stake in GVK Biosciences

This is the second domestic pure play pharma investment by the Goldman Sachs group. In November 2020, it pumped in $150 million in Kiran Mazumdar Shaw-led Biocon Biologics. Goldman Sachs is an active investor in India, deploying more than $3.6 billion in capital since 2006